A high CYFRA 21‑1 level indicates increased release of cytokeratin‑19 fragments into blood, commonly associated with non‑small cell lung cancer (especially squamous cell), and may reflect greater tumor burden, progression, or recurrence. It can also rise with other cancers or benign lung/renal conditions, so it’s not diagnostic alone; clinicians use it alongside imaging, biopsy and clinical assessment to guide diagnosis and monitor treatment response.

Yes. CYFRA 21-1 is a tumor marker — a soluble fragment of cytokeratin 19 measured in blood. It’s most useful in lung cancer (especially non‑small‑cell, often squamous cell), aiding diagnosis, prognosis, and monitoring treatment response or recurrence. Levels can be raised in other cancers and some benign lung conditions, so results must be interpreted with clinical findings and imaging.

CYFRA 21-1 is a cytokeratin 19 fragment used mainly in lung cancer. Its sensitivity is moderate (≈40–70%) while specificity is higher (≈80–95%), varying with cut-off and cancer subtype (higher in squamous cell). It's more useful for monitoring treatment response and recurrence than for screening, because false positives (benign lung disease, renal impairment) and false negatives can occur.

CA125 (cancer antigen 125) is a blood protein used as a tumor marker. Although chiefly linked to ovarian cancer, CA125 can be raised in some lung cancers—particularly with pleural involvement or advanced disease. It’s non‑specific and not diagnostic alone; clinicians interpret it alongside imaging and other tumor markers (for example CEA or CYFRA 21‑1) to monitor burden, progression, or treatment response.

A "bad" tumor marker has low sensitivity or specificity: it misses cancers (false negatives), is elevated in benign conditions (false positives), or doesn’t track tumor burden or treatment response. Such markers cause unnecessary tests, anxiety, or false reassurance. Useful markers are cancer-specific, correlate with disease stage, and reliably change with therapy; markers lacking these qualities are clinically unhelpful.

An ideal tumor marker is highly sensitive and specific to a particular cancer, detectable noninvasively (blood/urine), and reliably correlates with tumor burden, stage, prognosis, and treatment response. It has standardized, reproducible assays, low cost, and minimal false positives from benign conditions. Levels should change predictably with therapy and recurrence, enabling screening, diagnosis, monitoring, and risk stratification.